Psoriasis is a common skin disorder; knowledge of the factors that may induce, trigger, or
exacerbate the disease is of primary importance in clinical practice. Drug intake is a major …

Objectives. To identify all of the patients affected by chronic hepatitis C infection treated with
TNF-α blockers (adalimumab, certolizumab pegol, etanercept, golimumab and infliximab) in …

Background Interferon‐alpha (IFN‐α) therapy is used to treat hepatitis C infection. The
exacerbation and occurrence of psoriasis in hepatitis C patients treated with IFN‐α is …

Since the discovery of cytokines as key mediators in inflammation, targeting the cytokine
network has represented a promising therapeutic approach. Psoriasis and atopic dermatitis …

Hepatitis B virus (HBV) infection remains a serious global health problem despite the
availability of a highly effective vaccine. Approximately 5% of HBV‐infected adults develop …

Drug‐induced cutaneous eruptions are named among the most common side effects of
many medications. Thus, cutaneous drug eruptions are a common cause of morbidity and …

Purpose: To investigate the association between psoriasis and viral hepatitis. Methods:
Psoriasis patients were compared to controls regarding the prevalence of viral hepatitis in a …

Extrahepatic manifestations are frequently encountered among patients with chronic
hepatitis C virus (HCV) infection. Many of these manifestations are autoimmune disorders …

Chronic hepatitis C virus infection (HCV) is associated with extrahepatic manifestations,
including such dermatologic conditions as mixed cryoglobulinemia, porphyria cutanea tarda …

Psoriasis is a chronic inflammatory cutaneous disease with multifactorial pathogenesis
involving both genetic and environmental factors as well as the innate and acquired immune …